Introduction
============

Bladder cancer is the 6th leading cause of new cancer cases and 9th leading cause of cancer-associated mortality in males worldwide. An estimated 429,800 new cases of bladder cancer and 165,100 bladder cancer associated mortalities occurred in 2012 worldwide ([@b1-ol-0-0-6581]). The histological types of bladder cancer are quite diverse, and the vast majority of cases are urothelial cancer ([@b2-ol-0-0-6581]). However, urothelial cancer is also known to have different variants, as determined by histological features. Squamous differentiation, defined by the presence of keratinization or intercellular bridges, is the most common variant of urothelial cancer, with previous studies noting its presence in 16.8--22.1% of cases ([@b3-ol-0-0-6581]--[@b5-ol-0-0-6581]) ([Fig. 1](#f1-ol-0-0-6581){ref-type="fig"}). Glandular differentiation, characterized by intratumoral tubular or enteric gland-like spaces, is less common compared with squamous differentiation, with an incidence of ≤16% ([@b6-ol-0-0-6581]) ([Fig. 2](#f2-ol-0-0-6581){ref-type="fig"}). These two histological subtypes often coexist within the same tumor ([@b7-ol-0-0-6581],[@b8-ol-0-0-6581]).

It is controversial whether urothelial carcinoma of bladder (UCB) with squamous and/or glandular differentiation behave more aggressively compared with pure UCBs. Generally, squamous and/or glandular differentiation has been thought to have little clinical significance in urothelial carcinomas ([@b9-ol-0-0-6581]--[@b11-ol-0-0-6581]). However, previous studies have suggested that the presence of variant histology is usually associated with more aggressive behavior and a worse patient outcome ([@b3-ol-0-0-6581],[@b12-ol-0-0-6581]--[@b14-ol-0-0-6581]). The clinical management for patients with UCB with divergent histology remains controversial.

However, these aforementioned studies are largely limited to muscle invasive UCBs treated with radical cystectomy. The significance of squamous and/or glandular histological features, characterized at transurethral resection (TURBT), remains unclear ([@b15-ol-0-0-6581],[@b16-ol-0-0-6581]). The present study therefore aims to determine the prognostic relevance of squamous and/or glandular differentiation in patients with nonmuscle invasive urothelial carcinoma of bladder (NMIUCB) that have been treated with TURBT.

Materials and methods
=====================

### Ethics statement

The present study was approved by the Ethics Committee of the Second Hospital of Tianjin Medical University (Tianjin, China). The retrospective study conducted did not affect the clinical course of any patient, and all patient records were analyzed anonymously. Due to the retrospective nature of the study, written informed consent for each individual was not necessary.

### Patient characteristics

All clinical data were prospectively gathered from patient charts and electronic medical records. A total of 869 patients with NMIUCB who underwent TURBT between January 2006 and January 2011 were enrolled into the present study. The inclusion criteria for the study were: Patients who underwent TURBT as an initial treatment; a pathological diagnosis of tumors as NMIUCB \[noninvasive papillary urothelial carcinoma (pTa) + tumor invading into the lamina propria (pT1)\]; patients for whom a detailed assessment of primary tumor histology was available; and patients who received adjuvant intravesical chemotherapy following TURBT. Exclusion criteria for the present study include: An absence of urothelial carcinoma histology in the TURBT specimen; the presence of urethral or upper tract primaries, or distant metastasis at diagnosis; and the presence of carcinoma *in situ* (CIS) and other histological variants. For each patient, the following clinical factors were collected: Age, sex, tumor multiplicity, tumor size, pathological tumor stage and tumor grade. Tumor size was defined as being the greatest diameter observed during microscopic analysis of the surgical specimen.

### Surgical procedure and pathological evaluation

All patients were treated with TURBT according to the following standardized procedure used by all surgeons in the present study. All visible tumors or suspicious mucosal lesions were resected with a monopolar loop electrode until the tumor base reached the deep muscle layer and transparently showed perivesical fat. Tissue samples were collected and fixed in formalin and embedded in paraffin. Available hematoxylin and eosin stained slides (staining for 5 min at 25°C with hematoxylin and 30 s at 25°C with eosin) of tumor tissue samples (thickness 4 µm) were reassessed using a light microscope (magnification, ×100). The pathological stage and tumor grade were reassigned by a single genitourinary pathologist at the Second Hospital of Tianjin Medical University, according to the 2002 World Health Organization (WHO) tumor-node-metastasis classification of 6th American Joint Committee on Cancer and the 1973 WHO grading system, respectively ([@b17-ol-0-0-6581],[@b18-ol-0-0-6581]). Squamous differentiation was defined by the presence of intercellular bridges or keratinization and glandular differentiation was defined as gland formation in the tumor with or without mucin production ([@b19-ol-0-0-6581]). According to the published classification recommendations, tumors with any urothelial carcinoma (UC) component as well as a second, nonurothelial malignant component were considered to represent UC with histological differentiation. Thus, patients with pure non UC were not included in the present study.

### Initial adjuvant intravesical therapy

Due to the inaccessibility of the drug Bacillus Calmette-Guerin in China before 2015, all enrolled patients received the anthracycline antibiotic chemotherapy drugs including epirubicin or pirarubicin. The dosage and scheme used varied between patients as this observational study was based on a retrospective analysis. The schedule for instillation chemotherapy consisted of weekly instillations for 8 consecutive weeks and monthly instillations for 12 consecutive months. The chemotherapeutic drug used was either 40--60 mg epirubicin or 30 mg pirarubicin.

### Follow-up and clinical outcomes

Postoperative follow-up was conducted by rigid cystoscopy every 3 months for a period of 2 years, every 6 months thereafter until 5 years and then yearly according to the Chinese guidelines, which are the same as the US and European guidelines ([@b20-ol-0-0-6581]). The end points of the present study were recurrence and progression. Outcomes of interest in the present study were recurrence-free survival (RFS) and progression-free survival (PFS). The RFS period was estimated from the date of surgery to date of first clinical recurrence (any grade, any pathological stage of tumor or CIS). The PFS duration was calculated from the time of surgery to the date when the disease developed to a higher histological or pathological stage and/or to metastasis. For patients without recurrence and progression, the end point was the date of the last available follow-up cystoscopy.

### Statistical analysis

Statistical analysis was performed using the statistical software SPSS, version 20 (IBM SPSS, Armonk, NY, USA). Continuous variables according to the presence of the squamous and/or glandular differentiation were compared using the independent sample t-test, and categorical variables were compared using the χ2 test. RFS and PFS curves were calculated by the Kaplan-Meier method and differences were analyzed by the log-rank test. Univariate and multivariate Cox proportional hazard analysis were performed to verify independent predictive parameters of recurrence and progression. All tests were 2-sided, and P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

The clinicopathological demographics of patients with pure UCB, and those with UCB and squamous and/or glandular differentiation are presented in [Table I](#tI-ol-0-0-6581){ref-type="table"}. The mean age at initial TURBT was 64.89±10.28 years in patients with pure UCB and 66.16±11.02 years in patients with squamous and/or glandular differentiation. Among the 869 patients, 195 (22.4%) had UCB with squamous differentiation, 27 (3.1%) had glandular differentiation, and 10 (1.2%) had squamous and glandular differentiation, which is similar to the results of a previous study ([@b2-ol-0-0-6581]). Age, sex, tumor size, tumor multiplicity and pathological tumor stage did not differ depending on the presence of the squamous and/or glandular differentiation. However, high grade tumors were more common in UCB with squamous and/or glandular differentiation compared with pure UCB (58.62 vs. 29.04%, P\<0.001).

During the median 76.0 months follow-up, 89/232 patients with squamous and/or glandular differentiation and 149/637 patients with pure UCB experienced disease recurrence ([Table II](#tII-ol-0-0-6581){ref-type="table"}). Similarly, 27/232 patients with squamous and/or glandular differentiation and 72/637 patients with pure UCB achieved disease progression. Patients with squamous and/or glandular differentiation were significantly more likely to recur compared with those with pure UCB (38.36 vs. 23.39%, respectively, P\<0.001). However, no statistically significant difference was observed in the rates of progression between patients with squamous and/or glandular differentiation and those with pure UCB (11.64 vs. 11.30%, respectively, P=0.891).

[Figs. 3](#f3-ol-0-0-6581){ref-type="fig"} and [4](#f4-ol-0-0-6581){ref-type="fig"} show the Kaplan-Meier plots for recurrence-free and progression-free survival estimates stratified by pure UCB vs. those with squamous and/or glandular differentiation. Patients with squamous and/or glandular cell differentiated UCB had shorter mean RFS duration compared with those with pure UCB (80.5 vs. 93.0 months, respectively, P\<0.001). By contrast, no significant difference was observed between the PFS of the two groups (104.7 vs. 103.6 months, respectively, P=0.813).

The present study conducted additional analysis using Cox\'s proportional hazard regression analysis to evaluate the role of each variable in recurrence ([Table III](#tIII-ol-0-0-6581){ref-type="table"}). The results of univariate analysis revealed that tumor multiplicity \[hazard ratio (HR) 1.86, 95% confidence interval (CI) 1.44--2.40, P\<0.001\], tumor size (HR 1.82, 95% CI 1.41--2.35, P\<0.001), tumor grade (HR 1.78, 95% CI 1.38--2.30, P\<0.001), pathological tumor stage (HR 2.44, 95% CI 1.08--5.49, P=0.031) and the presence of squamous and/or glandular differentiation (HR 1.72, 95% CI 1.33--2.24, P\<0.001) were significant factors associated with disease recurrence.

However, in multivariate Cox\'s proportional hazard regression analysis, only tumor multiplicity (HR 1.73, 95% CI 1.34--2.24, P\<0.001), tumor size (HR 1.72, 95% CI 1.33--2.22, P\<0.001), tumor grade (HR 1.42, 95% CI 1.08--1.86, P=0.012) and the presence of squamous and/or glandular differentiation (HR 1.46, 95% CI 1.10--1.92, P=0.008) were demonstrated to be significant independent predictors of recurrence.

Discussion
==========

Bladder cancer comprises a wide range of histological types. UC is derived from uroepithelium, and is the most common type of bladder cancer accounting for \>90% of bladder cancer cases ([@b2-ol-0-0-6581]). UC is known to demonstrate variant histologic features, otherwise known as divergent differentiation. Squamous and glandular elements represent the most common types of divergent histology in primary UCB, and these features may coexist within a single tumor ([@b2-ol-0-0-6581]). However, the clinical significance of squamous and/or glandular differentiation remains uncertain ([@b11-ol-0-0-6581],[@b12-ol-0-0-6581],[@b14-ol-0-0-6581],[@b21-ol-0-0-6581]).

Generally, it has been considered that there are no prognostic differences between patients with UCB with and without differentiation ([@b9-ol-0-0-6581]--[@b11-ol-0-0-6581]). Kim *et al* ([@b11-ol-0-0-6581]) conducted a retrospective review of 1,013 patients who had undergone radical cystectomy, and reported that patients with urothelial carcinoma, and squamous and/or glandular differentiation were more likely to possess extravesical tumors and a node positive disease. Multivariate analysis controlling for clinicopathological variables revealed that squamous and/or glandular differentiation was not significantly associated with the risk of mortality from bladder cancer ([@b11-ol-0-0-6581]). Similarly, in a single referral center study of 2,444 patients who had undergone radical cystectomy with extended lymph node dissection, the outcomes of patients with UCB with squamous and/or glandular differentiation were similar to those of patients with pure UCB, considering comparable demographic, clinicopathological and management characteristics ([@b22-ol-0-0-6581]).

However, other studies contradict these findings, indicating that squamous and/or glandular differentiation appears to be an unfavorable prognostic feature in such patients undergoing radical cystectomy, which is possibly due to its association with high grade tumors ([@b3-ol-0-0-6581],[@b4-ol-0-0-6581],[@b13-ol-0-0-6581],[@b21-ol-0-0-6581],[@b23-ol-0-0-6581],[@b24-ol-0-0-6581]). Squamous and/or glandular differentiation is usually found in moderate to high grade tumors, and often has deeply invasive behavior. Antunes *et al* ([@b3-ol-0-0-6581]) identified that squamous differentiation was an independent prognostic factor for cancer specific survival in patients with bladder cancer that had been treated with radical cystectomy. In addition, Honma *et al* ([@b12-ol-0-0-6581]) reported that the existence of a squamous cell carcinoma component in the specimen may result in a strong impact on the development of local recurrence following radical cystectomy.

Treatment options for patients with UCB with squamous and/or glandular differentiation is currently debated. Previous studies have suggested that these variants may be more resistant to chemotherapy and radiation therapy compared with pure UCB ([@b13-ol-0-0-6581],[@b19-ol-0-0-6581],[@b25-ol-0-0-6581]). However, Scosyrev *et al* ([@b10-ol-0-0-6581]) reported that patients with squamous or glandular histological UCB variants exhibited an improved response to neoadjuvant chemotherapy \[methotrexate, vinblastine, doxorubicin (Adriamycin) and cisplatin\] in a post hoc analysis of a prospective trial. Additional studies are required in order to evaluate the role of chemotherapy and radiation therapy in UCBs with squamous and/or glandular differentiation.

The effect of squamous and/or glandular differentiation in transurethral resections of the bladder on prognosis also remains unclear. Billis *et al* ([@b15-ol-0-0-6581]) reported that urothelial bladder carcinomas with squamous and/or glandular differentiation were more aggressive neoplasms compared with pure UCBs. A statistically significant association was observed between higher stage and differentiation in two groups of urothelial carcinoma with and without squamous and/or glandular differentiation ([@b15-ol-0-0-6581]). Erdemir *et al* ([@b23-ol-0-0-6581]) reported that squamous and/or glandular differentiation was significantly associated with higher pathological stage and histological grade. Patients with variant UCB histology had a higher risk of disease recurrence and progression, and lower survival rates following TURBT compared with patients with pure UCB.

A limited number of studies have investigated the impact of squamous and/or glandular differentiation on oncologic outcomes in non-invasive UCB. In a study by Miller and Epstein([@b25-ol-0-0-6581]), the presence of glandular differentiation in noninvasive UCB was associated with an increased risk of developing to high-grade prognostically poor invasive bladder carcinomas including poorly-differentiated UCB.

Unlike previous studies, the emphasis of the present study was to investigate the impact of squamous and/or glandular differentiation on recurrence and progression rates in patients with NMIUCB following TURBT. All patients enrolled in the present study were pathologically diagnosed as having NMIUCB (pTa + pT1) and TURBT was performed as the initial treatment. The results demonstrated that patients with squamous and/or glandular differentiation had a higher recurrence rate and shorter mean RFS duration compared with patients with pure UC. However, no statistically significant difference was observed between the incidence of progression and mean PFS duration.

Multivariate Cox regression analysis revealed that squamous and/or glandular differentiation, tumor size, tumor count and tumor grade were independent prognostic factors of RFS. The most notable finding was the grade distribution of the tumors with differentiation. Patients with differentiation were significantly more likely to possess high grade tumors compared with those with pure UCB. These findings suggested that the presence of squamous and/or glandular differentiation in patients with NMUCB is associated with more aggressive behavior. Follow-up should therefore be closer for patients with squamous and/or glandular differentiation due to a higher risk of recurrence.

The present study was not devoid of limitations. Firstly, limitations occurred due to the retrospective nature of the present study, with there being nonrandomized samples from a single institution. In addition, a re-review of all specimens was not performed and therefore the present study relied on the pathologist to identify and report the variant histologies. Furthermore, the present study did not investigate the impact of squamous and glandular differentiation on NMUCB individually which may have a disparate prognostic importance.

In summary, the presence of squamous and/or glandular differentiation in NMIUCB identified at TURBT indicates a locally aggressive and advance disease. As an independent prognostic factor of recurrence, patients with the variant form of NMIUCB present a shorter RFS duration, and should therefore be followed up closely in case of recurrence.

The present study was funded by grants from The Natural Science Foundation of Tianjin (grant no. 14JCYBJC26300) and National Key Specialty Construction of Clinical Projects, The Natural Science Foundation of Tianjin (grant no. 15JCYBJC24600), and Tianjin Major Scientific and Technological special Project (grant no. 12ZCDZSY16900). The authors would like to thank all the study participants, urologists and study coordinators for their participation in the present study.
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###### 

Clinicopathological patient demographics stratified by squamous and/or glandular differentiation in TURBT specimen.

  Clinicopathological features       Pure UCB no. (%)   UCB + squamous/glandular differentiation (%)   P-value
  ---------------------------------- ------------------ ---------------------------------------------- ---------
  No. of patients                    637                232                                            
  Mean age at initial TURBT, years   64.89±10.28        66.16±11.02                                    
    \<65                             292 (45.84)        94 (40.52)                                     0.115
    ≥65                              345 (54.16)        138 (59.48)                                    
  Sex                                                                                                  
    Male                             525 (82.42)        182 (78.45)                                    0.184
    Female                           112 (17.58)        50 (21.55)                                     
  Tumor size, cm                                                                                       
    \<3                              437 (68.60)        149 (64.22)                                    0.223
    ≥3                               200 (31.40)        83 (35.78)                                     
  Multiplicity                                                                                         
    Single                           390 (61.22)        128 (55.17)                                    0.108
    Multiple                         247 (38.78)        104 (44.83)                                    
  Pathological tumor stage                                                                             
    pTa                              37 (5.81)          13 (5.60)                                      0.909
    pT1                              600 (94.19)        219 (94.40)                                    
  Tumor grade                                                                                          
    Low                              452 (70.96)        96 (41.38)                                     \<0.001
    High                             185 (29.04)        136 (58.62)                                    

Data are presented as the mean ± standard deviation. Tumor size was classified as being the largest diameter of the resected tumor. TURBT, transurethral resection; UCB, urothelial carcinoma of bladder; pTa, noninvasive papillary urothelial carcinoma; pT1, tumor invading into the lamina propria.

###### 

Distribution of the two groups in accordance with recurrence and progression.

  Recurrence and progression   Pure UCB no. (%)   UCB + squamous/glandular differentiation   P-value
  ---------------------------- ------------------ ------------------------------------------ ---------
  Recurrence                                                                                 
    Yes                        149 (23.39)        89 (38.36)                                 \<0.001
    No                         488 (76.61)        143 (61.64)                                
  Mean RFS, mo (range)         93.01 (2--114)     80.54 (3--113)                             \<0.001
  Progression                                                                                
    Yes                        72 (11.30)         27 (11.64)                                 0.891
    No                         565 (88.70)        205 (88.36)                                
  Mean PFS, mo (range)         104.74 (3--114)    103.65 (5--114)                            0.813

UCB, urothelial carcinoma of bladder; RFS, recurrence-free survival; PFS, progression-free survival; mo, months.

###### 

Univariate and multivariate analyses according to recurrence.

                                              Univariate          Multivariate                       
  ------------------------------------------- ------------------- -------------- ------------------- ---------
  Age, years                                                                                         
    \<65                                      1.16 (0.90--1.49)   0.265          --                  --
    ≥65                                                                                              
  Sex                                                                                                
    Male                                      1.08 (0.77--1.50)   0.657          --                  --
    Female                                                                                           
  Multiplicity                                                                                       
    Single                                    1.86 (1.44--2.40)   \<0.001        1.73 (1.34--2.24)   \<0.001
    Multiple                                                                                         
  Tumor size, cm                                                                                     
    \<3                                       1.82 (1.41--2.35)   \<0.001        1.72 (1.33--2.22)   \<0.001
    ≥3                                                                                               
  Tumor grade                                                                                        
    Low                                       1.78 (1.38--2.30)   \<0.001        1.42 (1.08--1.86)   0.012
    High                                                                                             
  Pathological tumor stage                                                                           
    pTa                                       2.44 (1.08--5.49)   0.031          2.04 (0.90--4.60)   0.088
    pT1                                                                                              
  Squamous and/or glandular differentiation                                                          
    Absent                                    1.72 (1.33--2.24)   \<0.001        1.46 (1.10--1.92)   0.008
    Present                                                                                          

HR, hazard ratio; CI, confidence interval; pTa, noninvasive papillary urothelial carcinoma; pT1, tumor invading into the lamina propria.
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